GLP-1 Weight-Loss Boom Linked to Surge in Poison Control Calls
A new study found that calls to poison control centers involving popular GLP-1 weight-loss drugs climbed sharply after semaglutide was approved for obesity in 2021, with most cases linked to medication mistakes that could have been avoided.
Health News is provided as a service to Medical Center Pharmacy site users by HealthDay. Medical Center Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.